Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: Based on class 1 evidence studies, first-line pharmacological treatment of cataplexy should be sodium oxybate. Second-line treatment should be antidepressants with norepinephrine/serotonine reuptake inhibitor venlafaxine based on its good benefit-risk ratio; however, this recommendation lacks class 1 evidence and is based on expert opinion only. Given the major developments in understanding the neurobiological basis of cataplexy, future therapeutic targets are clearly oriented toward immune-based therapies at early stages of the disease and hypocretin replacement therapy.
|
Authors | Régis Lopez, Yves Dauvilliers |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 14
Issue 7
Pg. 895-903
(May 2013)
ISSN: 1744-7666 [Electronic] England |
PMID | 23521426
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Antidepressive Agents
- Intracellular Signaling Peptides and Proteins
- Neuropeptides
- Orexins
- Serotonin Uptake Inhibitors
- Sodium Oxybate
|
Topics |
- Adrenergic Uptake Inhibitors
(administration & dosage, pharmacology, therapeutic use)
- Antidepressive Agents
(administration & dosage, therapeutic use)
- Cataplexy
(drug therapy, physiopathology)
- Drug Therapy, Combination
- Humans
- Intracellular Signaling Peptides and Proteins
(metabolism)
- Neuropeptides
(metabolism)
- Orexins
- Selective Serotonin Reuptake Inhibitors
(administration & dosage, therapeutic use)
- Sodium Oxybate
(administration & dosage, pharmacology, therapeutic use)
|